Short Interest in Gain Therapeutics Surges 64.5% in December
Gain Therapeutics, Inc. (NASDAQ: GANX) experienced a substantial increase in short interest in December 2023, with figures rising by 64.5% from the previous month. As of December 15, short interest totaled 2,073,310 shares, up from 1,260,732 shares on November 30. Currently, 5.8% of the company’s shares are sold short, indicating a notable shift in investor sentiment.
The average daily trading volume for Gain Therapeutics is 1,377,957 shares, leading to a days-to-cover ratio of approximately 1.5 days. This metric provides insight into how long it would take for investors to cover their short positions, reflecting the stock’s liquidity and volatility.
During midday trading on Friday, the stock saw a slight decline, trading down $0.07 to reach $3.15. A total of 576,275 shares changed hands, significantly below the average volume of 2,177,527 shares. The company’s market capitalization stands at $121.16 million, with a price-to-earnings ratio of -5.16 and a beta of 0.06.
Financial Metrics and Trading Activity
Gain Therapeutics has established a solid financial position, with a quick ratio and current ratio both at 2.52 and a low debt-to-equity ratio of 0.05. Over the past year, the stock has fluctuated between a low of $1.41 and a high of $4.34.
The company reported its earnings results on November 12, with earnings per share (EPS) at ($0.15), aligning with analysts’ expectations. Looking ahead, research analysts project that Gain Therapeutics will report an EPS of ($1) for the current fiscal year.
Analysts have varied opinions on the stock’s future. Maxim Group recently increased its price target for Gain Therapeutics from $5.00 to $7.00 and assigned a “buy” rating in an October report. Roth Capital echoed this sentiment, maintaining a “buy” rating with a target price of $10.00 on December 19. Conversely, Weiss Ratings issued a “sell (e+)” rating on December 22, indicating some divergence among analysts regarding the stock’s outlook.
Analyst Ratings and Market Consensus
The current consensus among analysts is a “Moderate Buy,” with six analysts recommending a buy and one suggesting a sell. MarketBeat.com reports a consensus target price of $8.67, reflecting a potential upside for investors.
Gain Therapeutics is known for its focus on precision therapeutics aimed at treating neurodegenerative and rare diseases. Utilizing its proprietary allosteric modulation platform, AlphaTarget, the company aims to develop small molecule modulators that can effectively correct protein folding and function. Its lead candidate, GT-022, is in development for Gaucher disease, a rare condition marked by enzyme deficiency.
As Gain Therapeutics continues to navigate the complexities of the biopharmaceutical landscape, investors and analysts alike will be closely watching its next moves, particularly in light of the recent surge in short interest and varied analyst ratings.
